Updates on nanotechnology to deliver therapies?

Save as Favorite
Sign in to receive recommendations (Learn more)
Question from Ann: Is there any update about nanotechnology to deliver therapies in a targeted way and thus help overcome toxicity?
Answers - Andrew D. Seidman, M.D. There is an approved chemotherapeutic agent for metastatic breast cancer known as albumin-bound nab-paclitaxel (brand name: Abraxane). This drug uses small protein particles to enhance the delivery of paclitaxel in an effort to improve effectiveness and reduce toxicity. Randomized trials have shown that this agent compares quite favorably to older taxanes Taxol and Taxotere.

The Ask-the-Expert Online Conference called Updates From the 2010 ASCO Annual Meeting featured Andrew Seidman, M.D. and Beth Baughman DuPree, M.D., F.A.C.S. answering your questions about the latest updates on breast cancer risk, screening techniques, treatment options, and more.

Editor's Note: This conference took place in June 2010.

The materials presented in these conferences do not necessarily reflect the views of Breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.

A production of LiveWorld, Inc.
Copyright 2010. All rights reserved.



Springappeal300x125 nm a
Back to Top